China, AstraZeneca

AstraZeneca Could Pay $4.5 Million In China Scandal. Here's Why Shares Jumped.
AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.
AstraZeneca’s shares rise as it addresses China investigation
In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company confirmed that its Chinese business is under investigation for alleged unpaid import taxes on certain cancer drugs, including Imfinzi (durvalumab) and Imjudo (tremelimumab).
AstraZeneca sales jump despite troubles in China
Sales in China fell 3 per cent during the quarter. AstraZeneca said this was mainly because the winter had been mild, causing a drop in sales of respiratory drugs used to treat viral infections. It also cited annual budget caps at Chinese hospitals.
AstraZeneca shares rise as China probe update reassures
AstraZeneca on Thursday said it could face a fine of up to $4.5 million in China over suspected unpaid import taxes, raising investor hopes that the impact of several probes in the country could be minor and leading its shares to rise about 5%.
Pharmalittle: We’re reading about a China probe of AstraZeneca, a ‘troubling’ Super Bowl ad, and more
A pharma industry group asked the FDA to "take action" against a "dangerous" ad Hims & Hers plans to run during the Super Bowl
AstraZeneca gains as Q4 results clear China overhang
AstraZeneca (AZN) stock rises as its Q4 results which exceeded Street forecasts address concerns over its China investigation. Read more here.
AstraZeneca CEO says company has no access to executive Wang, in detention in China
AstraZeneca has been approached a couple of times by Chinese authorities about their investigation into the drugmaker's ...
Pharmaceutical giant AstraZeneca faces potential fines in China over import taxes
AstraZeneca appointed a new president for its China operations following the arrest of former executive Leon Wang along with ...
AstraZeneca ‘very disappointed’ after ditching £450m Liverpool vaccine site
The boss of drugmaker AstraZeneca has said he was “very disappointed” with the firm’s move to scrap plans for a £450 million ...
devdiscourse2d
Health News Highlights: Stable Pig Prices, Investor Concerns, and Medical Developments
This summary covers recent health news, including stable pig prices in Germany, investor focus on AstraZeneca's China probe, ...
Reuters3d
AstraZeneca shareholders say they need clarity on China investigations
LONDON, Feb 5 (Reuters) - AstraZeneca (AZN.L), opens new tab investors ... The group said on Oct. 31 that its China head Leon Wang, who also led its international business as an executive vice ...
AstraZeneca continues to ‘fully cooperate’ with Chinese authorities
The company said, “In relation to the illegal drug importation allegations, in January 2025, AstraZeneca (AZN) received a Notice of Transfer to ...
AstraZeneca faces potential fines in China over import taxes
Drugmaker AstraZeneca has warned it could face a fine in China over possible unpaid import taxes, as it revealed strong sales ...
AstraZeneca faces potential fines in China over unpaid import taxes
AstraZeneca said the taxes related to two cancer drugs, Imfinzi and Imjudo, and that it was continuing to co-operate with ...